Aptamer Group PLC AGM Statement (9073W)

TIDMAPTA

RNS Number : 9073W

Aptamer Group PLC

15 December 2023

15 December 2023

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Annual General Meeting Statement

Aptamer Group plc (AIM: APTA), the developer of novel Optimer (R) binders to enable innovation in the life sciences industry, will hold its Annual General Meeting (AGM) at 10:00 am today at the offices of Aptamer Group plc, Windmill House, Innovation Way, York, YO10 5BR.

Since the Group was recapitalised in August 2023, it has made significant technical and commercial progress. This includes a reduction of the cost base, streamlining of the production processes for increased production capacity and a reduction of material requirements from customers. The Group has continued to build and convert the commercial pipeline, including the recent announcement of a partnership with a genetic medicines company for Optimer development to support targeted delivery of new medicines. No new material information will be provided.

The results of the AGM will be announced to the London Stock Exchange and placed on the Group's website, in the usual way, as soon as practicable after the conclusion of the AGM.

- ENDS -

For further information, please contact:

 
 Aptamer Group plc 
  Steve Hull                                    [phone] 
 SPARK Advisory Partners Limited - Nominated 
  Adviser 
  Andrew Emmott / Mark Brady / Adam Dawes       [phone] 
                                               ----------------------- 
 T urner Pope I nvestments (TPI) Limited 
  - B roker 
  J ames Pope / Andrew Thacker                  [phone] 
                                               ----------------------- 
 

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer (R) platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over $170 billion.

Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGMTIBMTMTMBTRJ

(END) Dow Jones Newswires

December 15, 2023 02:00 ET (07:00 GMT)